Tecentriq, is a prescription medicine used to treat adults with mUC, when the bladder cancer has spread or cannot be removed by surgery
Metastatic Urothelial Cancer (mUC) is an aggressive form of bladder cancer and one of the 10 most common cancers in the world that contribute 3.4 per cent to the global cancer burden. Tecentriq, is a prescription medicine used to treat adults with mUC, when the bladder cancer has spread or cannot be removed by surgery.
Recently, the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) has recommended that there is no objection for change in an indication of Tecentriq in locally
advanced or metastatic Urothelial Carcinoma indication, in line with US FDA (Food and Drug Administration) approvals. This is a promising development for cancer patients in India.
Commenting on the same, Dr Sudhir Rawal, Medical Director, Chief Uro-Oncology, Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC) said, “Given the limited awareness of the disease, Metastatic Urothelial Cancer (mUC) is usually detected in late stages. This type of cancer has high mutational complexity and hence responds better to the use of immunotherapy and targeted drugs. The recent decision by SEC is a welcome move and brings immense hope for cancer patients in India
as it enables us to continue having an immunotherapy option to treat/manage mUC. It can help improve the longevity and quality of life for people suffering from mUC.”